NRx Pharmaceuticals Completes Ketamine Process Validation

NRx Pharmaceuticals completed three commercial process validation lots and reported two-year room-temperature stability for preservative-free ketamine ahead of a Nov. 10 GDUFA goal date for its ANDA.